Investor Presentation - First Six Months of 2021

38 Investor presentation First six months of 2021 B-cell function Diabetes is a chronic disease requiring treatment intensification over time Diet and exercise Time 100% OAD GLP-1 Distribution of patients and value across treatment classes 5% 17% 80% 44% 16% 60% 23% 18% Insulin 40% 4% 8% 20% 39% 26% 0% Patients Value Insulin I GLP-1 SGLT-2i DPP-IV Traditional OADs Note: Patient distribution across treatment classes is indicative and based on data for the USA, Germany and France. Other OADs cover: metformin, sulfonylurea, thiazolidinediones. Source: IQVIA PharMetrix claims data, IQVIA disease analyser, IQVIA MIDAS; value figures based on IQVIA MAT, May 2021 OAD: Oral anti-diabetic Novo NordiskⓇ

View entire presentation